| Title: |
Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma |
| Authors: |
Camus, Vincent; Molina, Thierry; Desmots-Loyer, Fabienne; Blanc-Durand, Paul; Kanoun, Salim; Moslemi, Amine; Ruminy, Philippe; Le Gouill, Steven; Ghesquières, Hervé; Obéric, Lucie; Morschhauser, Franck; Tilly, Hervé; Ribrag, Vincent; Houot, Roch; Thieblemont, Catherine; Maisonneuve, Herve Gerard; Claves, Fabien; Bouabdallah, Krimo; Haioun, Corinne; Damaj, Gandhi Laurent; Fornecker, Luc-Mathieu; Noel, Robin; Feugier, Pierre; Sibon, David; Cartron, Guillaume; Bonnet, Christophe; Bernard, Wivine; Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline; Jais, Jean-Philippe; Brière, Josette; Rossi, Cédric; Elsensohn, Mad-Hélénie; Chartier, Loic; Itti, Emmanuel; Jardin, Fabrice; Fest, Thierry |
| Contributors: |
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel); Hôpital Necker - Enfants Malades AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Hospitalier Universitaire Rennes; CHU Henri Mondor Créteil; Groupe Henri Mondor-Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre de Recherches en Cancérologie de Toulouse (CRCT); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Toulouse (EPE UT); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse); CHU Amiens-Picardie; Institut Curie Paris; Centre Hospitalier Lyon Sud CHU - HCL (CHLS); Hospices Civils de Lyon (HCL); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037); Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hôpital Claude Huriez Lille; Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Institut Gustave Roussy (IGR); Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC); Université de Rennes (UR)-Établissement Français du Sang Bretagne Rennes (EFS Bretagne - Rennes); Établissement Français du Sang La Plaine Saint-Denis (EFS)-Établissement Français du Sang La Plaine Saint-Denis (EFS)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hopital Saint-Louis AP-HP (AP-HP); Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée); CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble (CHUGA); CHU Pessac; Service de médecine nucléaire CHU Caen; Université de Caen Normandie (UNICAEN); Normandie Université (NU)-Normandie Université (NU)-CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie (CHU Caen Normandie); Normandie Université (NU); Institut de Cancérologie de Strasbourg Europe (ICANS); Institut Paoli-Calmettes (IPC); Fédération nationale des Centres de lutte contre le Cancer (FNCLCC); Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL); CHU Montpellier = Montpellier University Hospital; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Institut de Génétique Moléculaire de Montpellier (IGMM); Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM); Centre Hospitalier Universitaire de Liège (CHU-Liège); Université Catholique de Louvain = Catholic University of Louvain (UCL); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); IFR de Saint-Louis - Institut universitaire d'hématologie (IFR105 - IUH); Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis AP-HP (AP-HP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); The Lymphoma Academic Research Organisation Lyon (LYSARC) |
| Source: |
ISSN: 2473-9529. |
| Publisher Information: |
CCSD; The American Society of Hematology |
| Publication Year: |
2025 |
| Collection: |
Université Toulouse III - Paul Sabatier: HAL-UPS |
| Subject Terms: |
[SDV.CAN]Life Sciences [q-bio]/Cancer |
| Description: |
International audience ; The GAINED study (NCT01659099) was a randomized phase 3 trial comparing obinutuzumab (G) to rituximab (R) plus ACVBP or CHOP14 induction, followed by PET-guided consolidation. This post-hoc analysis aimed to detail the outcomes of primary mediastinal B-cell lymphoma (PMBL) patients, verified through expert pathological review and the use of gene-expression profiling (GEP) and Next-Generation sequencing. Of the centrally reviewed 620 patients, 138 (22.3%) confirmed PMBL cases were analyzed. Baseline characteristics included a median age of 33.5 years, 63.8% female, 55.1% stage III-IV, 90.6% elevated LDH, 87.6% ECOG 0-1, 62.3% extranodal involvement, 52.6% aaIPI 2-3, and 53.6% Bulk (>10cm). Induction regimens were R/G-CHOP14 (56.9%) and R/G-ACVBP (43.1%). Post-induction treatments, based on interim PET (iPET) results, included: standard consolidation chemotherapy (59.8%) if ΔSUVmax >66% after cycle 2 and >70% after cycle 4 (PET2−/4−), intensive treatment and autologous transplantation (26.8%) if PET2+/4-, and salvage therapy (13.4%) if PET4+ (ΔSUVmax ≤70%). Among patients with GEP data (n=107), 38 (35.5%) were PDL1high/PDL2high. Key somatic mutations data (n=87) included SOCS1 (70.1%), B2M (56.3%), STAT6 (49.4%), TNFAIP3 (47.1%), GNA13 (39.1%), CIITA (37.9%), CD58 (36.8%), and TP53 (29.9%). After a median follow-up of 39.5 months, 2-year PFS and OS rates were 86.2% and 93.2%, respectively. In a multivariate model including Bulk, aaIPI, and ΔSUVmax PET2/PET4, only Bulk and ΔSUVmax PET4 ≤70% were associated with shorter PFS (HR 4.39 [1.28-15.11] and 4.95 [1.71-14.3], respectively), while none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population.Clinical trial registration information (if any): NCT01659099 |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40030008; PUBMED: 40030008 |
| DOI: |
10.1182/bloodadvances.2024015577 |
| Availability: |
https://hal.science/hal-04982054; https://hal.science/hal-04982054v1/document; https://hal.science/hal-04982054v1/file/blooda_adv-2024-015577-main.pdf; https://doi.org/10.1182/bloodadvances.2024015577 |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.FE52B7B0 |
| Database: |
BASE |